Literature DB >> 812871

Human platelet factor 4: Purification and characterization by affinity chromatography. Purification of human platelet factor 4.

S P Levine, H Wohl.   

Abstract

Platelet factor 4 is a low molecular weight protein contained in the storage granules of platelets and released during aggregation with a variety of aggregating agents. In vitro, it is a potent antiheparin. This property has been used for a rapid, simple purification procedure using affinity chromatography on heparin epsilon-aminocaproic aced Sepharose. Supernatants collected from outdated platelet concentrates, or platelet extracts prepared from washed, outdate platlets themselves, are first precipitated with 50% ammonium sulfate. The supernatant is dialyzed and applied to the affinity column. Contaminating proteins are washed from the column with 0.5 M NaCl in 0.005 M sodium barbital buffer, pH 7.4 and the column is then eluted with a gradient of 0.5 to 3.0 M NaCl in 0.005 M sodium barbital buffer, pH 7.4. When prepared from platelet extracts, a single protein peak with high platelet factor 4 activity is eluted at 0.9 to 1.0 M NaCl. The peak fractions demonstrate a single band on Na dodecyl-SO4-polyacrylamide gel electrophoresis. The molecular weight as determined by Na dodecyl-SO4 gel electrophoresis was 11,600 +/- 330, and was 40,000 by gel filtration.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 812871

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Thrombin generation and secretion of platelet Factor 4 during blood clotting.

Authors:  M A Shuman; S P Levine
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

2.  A compilation of amino acid analyses of proteins. XVIII. Residues per thousand residues--5.

Authors:  D M Kirschenbaum
Journal:  Appl Biochem Biotechnol       Date:  1983-08       Impact factor: 2.926

3.  Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity.

Authors:  J Moroianu; J F Riordan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

4.  Optimal techniques for the immunocytochemical demonstration of beta-thromboglobulin, platelet factor 4, and fibrinogen in the alpha granules of unstimulated platelets.

Authors:  P E Stenberg; M A Shuman; S P Levine; D F Bainton
Journal:  Histochem J       Date:  1984-09

5.  Immunological localisation of beta-thromboglobulin and platelet factor 4 in human megakaryocytes and platelets.

Authors:  K M McLaren; D S Pepper
Journal:  J Clin Pathol       Date:  1982-11       Impact factor: 3.411

6.  Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.

Authors:  D M Tollefsen; C A Pestka
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

7.  Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium.

Authors:  C Busch; W G Owen
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

8.  Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.

Authors:  N Duval; C Lunven; D P O'Brien; A Grosset; S E O'Connor; C N Berry
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

9.  Stimulation of human leukocyte elastase by platelet factor 4. Physiologic, morphologic, and biochemical effects on hamster lungs in vitro.

Authors:  S A Lonky; H Wohl
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

10.  Identification and characterization of PF4varl, a human gene variant of platelet factor 4.

Authors:  C J Green; R S Charles; B F Edwards; P H Johnson
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.